{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T19:20:24Z","timestamp":1782674424920,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Study was sponsored by the Canadian Myeloma Research Group (CMRG) with support from Glaxo-Smith-Kline"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01135-2","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T09:04:06Z","timestamp":1726045446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed\/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-4368","authenticated-orcid":false,"given":"Arleigh","family":"McCurdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-4642","authenticated-orcid":false,"given":"Donna","family":"Reece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Louzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Parkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibraheem","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniba","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-3215","authenticated-orcid":false,"given":"Engin","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"1135_CR1","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.clml.2022.03.002","volume":"22","author":"H Mian","year":"2022","unstructured":"Mian H, Reece D, Masih-Khan E, McCurdy A, Kardjadj M, Jimenez-Zepeda VH, et al. Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007\u20132018: Retrospective Analysis from the Canadian Myeloma Research Group Database. Clin Lymphoma Myeloma Leuk. 2022;22:608\u201317.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1135_CR2","doi-asserted-by":"crossref","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E, Escalante F, Queiz\u00e1n JA, B\u00e1rez A, et al. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. Cancers. 2023;15:1558.","DOI":"10.3390\/cancers15051558"},{"key":"1135_CR3","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.3324\/haematol.2023.282905","volume":"108","author":"A McCurdy","year":"2023","unstructured":"McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, et al. Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. 2023;108:3384\u201391.","journal-title":"Haematologica"},{"key":"1135_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022;387:132\u201347.","journal-title":"N Engl J Med"},{"key":"1135_CR5","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","volume":"127","author":"P Moreau","year":"2016","unstructured":"Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016;127:2569\u201374.","journal-title":"Blood"},{"key":"1135_CR6","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:1582\u201396.","journal-title":"Lancet Oncol"},{"key":"1135_CR7","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023;41:1590\u20139.","journal-title":"J Clin Oncol"},{"key":"1135_CR8","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1200\/JCO.21.02734","volume":"41","author":"P Sonneveld","year":"2023","unstructured":"Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023;41:1600\u20139.","journal-title":"J Clin Oncol"},{"key":"1135_CR9","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","volume":"7","author":"SZ Usmani","year":"2023","unstructured":"Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Adv. 2023;7:3739\u201348.","journal-title":"Blood Adv"},{"key":"1135_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","volume":"23","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022;23:416\u201327.","journal-title":"Lancet Oncol"},{"key":"1135_CR11","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1200\/JCO.21.00972","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021;39:2430\u201342.","journal-title":"J Clin Oncol"},{"key":"1135_CR12","doi-asserted-by":"crossref","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10:e825\u201337.","DOI":"10.1016\/S2352-3026(23)00217-X"},{"key":"1135_CR13","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:1378\u201390.","journal-title":"Lancet Oncol"},{"key":"1135_CR14","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9:e810\u201321.","journal-title":"Lancet Haematol"},{"key":"1135_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36:1371\u20136.","journal-title":"Leukemia"},{"key":"1135_CR16","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1182\/blood-2022-168843","volume":"140","author":"A Visram","year":"2022","unstructured":"Visram A, De La Torre A, White D, Kardjadj M, Masih-Khan E, Chu MP, et al. Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 2022;140:4287\u20139.","journal-title":"Blood"},{"key":"1135_CR17","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338.","journal-title":"Blood"},{"key":"1135_CR18","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4:4538\u201349.","journal-title":"Blood Adv"},{"key":"1135_CR19","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985\u20131005.","journal-title":"Leukemia"},{"key":"1135_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"1135_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"1135_CR22","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641\u201353.","journal-title":"Lancet Oncol"},{"key":"1135_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6","volume":"9","author":"S Trudel","year":"2019","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9:37.","journal-title":"Blood Cancer J"},{"key":"1135_CR24","doi-asserted-by":"crossref","unstructured":"Trudel S, McCurdy A, Louzada ML, Parkin S, White D, Chu MP, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in refractory multiple myeloma: a phase 1\/2 trial. Nat Med. 2023;30:543\u201351.","DOI":"10.1038\/s41591-023-02703-y"},{"key":"1135_CR25","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1135_CR26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","volume":"9","author":"AV Farooq","year":"2020","unstructured":"Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, et al. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther. 2020;9:889\u2013911.","journal-title":"Ophthalmol Ther"},{"key":"1135_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol"},{"key":"1135_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N. Engl J Med. 2022;387:495\u2013505.","journal-title":"N. Engl J Med"},{"key":"1135_CR29","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"1135_CR30","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"CD Schinke","year":"2023","unstructured":"Schinke CD, Touzeau C, Minnema MC, van de Donk N, Rodr\u00edguez-Otero P, Mateos MV, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8036.","journal-title":"J Clin Oncol"},{"key":"1135_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, et al. Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study. Blood. 2021;138:157\u201360.","journal-title":"Blood"},{"key":"1135_CR32","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","volume":"41","author":"Y Lin","year":"2023","unstructured":"Lin Y, Martin TG, Usmani SZ, Berdeja JG, Jakubowiak AJ, Agha ME, et al. CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41:8009.","journal-title":"J Clin Oncol"},{"key":"1135_CR33","doi-asserted-by":"publisher","first-page":"LBA106","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA106","volume":"41","author":"B Dhakal","year":"2023","unstructured":"Dhakal B, Yong K, Harrison SJ, Mateos MV, Moreau P, van de Donk N, et al. First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. J Clin Oncol. 2023;41:LBA106\u2013LBA.","journal-title":"J Clin Oncol"},{"key":"1135_CR34","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"1135_CR35","doi-asserted-by":"publisher","first-page":"8013","DOI":"10.1200\/JCO.2022.40.16_suppl.8013","volume":"40","author":"C Touzeau","year":"2022","unstructured":"Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, et al. Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents. J Clin Oncol. 2022;40:8013.","journal-title":"J Clin Oncol"},{"key":"1135_CR36","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","volume":"41","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Lesokhin AM, Mohty M, Niesvisky R, Maisel C, Arnulf B, et al. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies. J Clin Oncol. 2023;41:8008.","journal-title":"J Clin Oncol"},{"key":"1135_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Mateos M-V, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk N, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141:219\u201330.","journal-title":"Blood"},{"key":"1135_CR38","doi-asserted-by":"publisher","first-page":"10124","DOI":"10.1182\/blood-2022-164929","volume":"140","author":"M Hultcrantz","year":"2022","unstructured":"Hultcrantz M, Kleinman D, Vij R, Escalante F, Kotoswky N, Bitetti J, et al. Belantamab Mafodotin (Belamaf) for Relapsed\/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study. Blood. 2022;140:10124\u20136.","journal-title":"Blood"},{"key":"1135_CR39","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VT, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10:e801\u2013e12.","journal-title":"Lancet Haematol"},{"key":"1135_CR40","doi-asserted-by":"publisher","first-page":"8050","DOI":"10.1200\/JCO.2023.41.16_suppl.8050","volume":"41","author":"E Terpos","year":"2023","unstructured":"Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, et al. Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1\/2, prospective, open-label, BelaRd study. J Clin Oncol. 2023;41:8050.","journal-title":"J Clin Oncol"},{"key":"1135_CR41","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1182\/blood-2021-153315","volume":"138","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Alonso Alonso A, Quach H, Koh Y, Guenther A, Min C-K, et al. DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma. Blood. 2021;138:2738.","journal-title":"Blood"},{"key":"1135_CR42","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodriguez-Otero P, et al. Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022;387:2232\u201344.","journal-title":"N Engl J Med"},{"key":"1135_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-139785","volume":"136","author":"S Trudel","year":"2020","unstructured":"Trudel S, Davis R, Lewis NM, Bakshi KK, Chopra B, Montes de Oca R, et al. DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM). Blood. 2020;136:4.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01135-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01135-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01135-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T09:04:33Z","timestamp":1726045473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01135-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1135"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01135-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: AM received honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi, and GSK. DR received research funding and honoraria from, and is on the advisory board of, Janssen, BMS, and Takeda; received research funding from Millennium Pharmaceuticals; and received honoraria from Amgen, Sanofi, and GSK. ML received research support from BMS\/Celgene and Janssen; and honoraria from BMS\/Celgene, Janssen, Gilead, AbbVie, AstraZeneca, and Takeda. SP received consultancy honoraria from Janssen, BMS, FORUS, and Apotex; study funding from GSK; and funding from BMS. DW received honoraria from Amgen, Antengene, BMS, FORUS Therapeutics, GSK, Janssen, Karyopharm, Pfizer, Sanofi, and Takeda. MC received research support from BMS\/Celgene and Janssen; and honoraria from BMS\/Celgene, Janssen, Gilead, AbbVie, AstraZeneca, and Takeda. RK received honoraria from Akcea Therapeutics, Amgen, BMS, Janssen, Merck, Sanofi, Celgene, Pfizer, and Takeda; received research funding from Merck and Sanofi; and is a current equity holder in the private company Karyopharm. HM received advisory fees from Janssen, Takeda, Amgen, Pfizer, BMS, FORUS, and Sanofi; received research funding from Janssen; and is supported by the early career award from Hamilton Health Sciences. IO participated in advisory boards for and received honoraria from Amgen, BMS, Celgene, FORUS Therapeutics, Janssen, Pfizer, Sanofi-Genzyme, and Takeda; and received research funding from Janssen. JS, AK, and EG are employees of CMRG. ST received grant support from GSK, Bristol Myers Squibb (BMS), Janssen, Pfizer, Amgen, Roche, and Genentech; consulting fees from BMS, GSK, and Roche; and honoraria from BMS, Janssen, Amgen, Sanofi, and Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial was conducted in accordance with the Declaration of Helsinki, International Council Harmonization Good Clinical Practice Guidelines, local regulation governing the conduct of clinical studies and institutional guidelines. Approval to conduct the trial was provided by Ontario Cancer Research Ethics Board (OCREB; IRB00003960); project ID 1598. Informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"155"}}